Cambridge, United States
Xbiome, established in 2017, is touted as China's leading AI-driven microbiome drug development company. As a pioneer in AI-based solutions, it aims to transform the biotechnology and pharmaceutical sectors, focusing on gut microbiome using sophisticated AI techniques. This approach to health leverages the gut's microbial ecosystem, known to affect over 50 human diseases, by harnessing AI and bioinformatics for drug development.
Their innovative platform, which integrates microbial technologies and gut microbiome insights, significantly enhances the speed and success rate of new treatments. With headquarters in the United States, Xbiome is poised for significant growth, reflected in their robust Series B investment of $100.00M as of December 22, 2021. The funding round saw contributions from prominent investors like Gaorong Capital, Sky9 Capital, and Legend Capital among others. This solid backing and innovative approach position Xbiome as a compelling opportunity for investors focused on the future of personalized medicine.
